AUA Annual Urology Advocacy Summit (2019)

Washington, DC US
March 4, 2019 to March 6, 2019

The 2019 Annual Urology Advocacy Summit is an innovative symposium that brings together all facets of the urology community, including all members of the urologic care team, researchers, patient education groups, advocacy societies and subspecialties. The three-day event will expand and strengthen urology's credible and longstanding work with lawmakers on Capitol Hill, government agencies and state legislatures by cultivating and empowering specialty-specific advocates to promote health policy initiatives that benefit their community.

Target Audience

  • Urologist
  • Resident
  • Advanced Practice Provider (Nurse Practitioners & Physician Assistants)
  • Non-Urologist (MD or DO)
  • Research/Scientist
  • Nurse
  • Medical Technician/Assistant
  • Medical Student
  • Practice Manager

Learning Objectives

After attending the Summit and the CME sessions, participants should be able to:

  1. General Session – Prostate Cancer Advocacy 
    • Describe and promote the need for active surveillance in men with prostate cancer.  
    • Explain the effectiveness of the United States Preventative Services Task Force’s change to the grade recommendation for prostate cancer screening. 
    • Evaluate the United States Preventive Services Task Force Guidelines and existing data.
    • Discuss potential collaboration with state legislatures, patient advocacy communities and others to draft model language on improving prostate cancer screening coverage.
  2. General Session – Research
    • Discuss the differences in the behavior of prostate cancer in African American men and the need to advocate for increased research.
    • Evaluate the need for increased clinical research studies of high at-risk populations subjected to health care disparities. 
  3. Regulatory Burdens to Care
    • Identify the efficiencies in electronic health records.
    • Discuss the role of step therapy and prior authorization, its impact on personalized medicine, and its barriers to care and physician treatment.
  4. Transgendered Care
    • Describe advocacy issues facing pediatric urology, transgendered care and sex development as a whole.
    • Explain the current advocacy efforts regarding disorders of sex development, and transgendered care at the state and local levels.
    • Outline the best practices in gender medicine, including gender-affirming surgery. 
  5. Access to Rural Care
    • Describe and determine the role of nurse practitioners and urologists in smaller clinic versus academic setting.
    • Explain and measure the ability to find appropriately trained physicians to treat adults with congenital conditions.
    • Describe the growing concern for Medicare beneficiaries in rural America with regard to the aging urologic workforce, and increased centralization of urologists in larger cities.
  6. Stark Law under MACRA
    • Explain how Stark Reform works to allow independent urologic practices to thrive under MACRA while maintaining the In-Office Ancillary Service Exception (IOASE).
    • Analyze and apply regulatory implementation of MACRA.
    • Examine patient access to physician administered cancer therapy through Medicare Part B.
  7. Opioids
    • Summarize how electronic residency application services’ (ERAS) protocolized post-surgery care pathways for cystectomy/nephrectomy: 1) decrease opiate use post-operatively, 2) increase post-operative care quality and 3) reduce post-operative care costs. 
  8. Veterans Healthcare Roundtable
    • Examine veteran’s care regarding fertility and prostate cancer.
  9. Fertility Care and Coverage 
    • Evaluate sexual and reproductive health of veterans and the ability to find appropriately trained physicians to treat adults with congenital conditions.
    • Explain the current state advocacy efforts in mandating insurance coverage for fertility preservation.
  10. Access to Care – Workforce 
    • Evaluate the urology work force, and describe where shortages exist. 
    • Discuss how to integrate Advanced Practice Providers (APPs) into urologic practices; and how employing APPs can make a positive impact on patient access and care. 
  11. Prescription Drug Price Negotiation 
    • Explain the need for drug price controls to be lifted to allow Medicare to negotiate with pharmaceutical industry in order to provide discounted pricing for some patients.   
  12. Advanced Payment Models/Value Based Payments
    • Evaluate the status of advanced APM’s in urology, 
    • Assess the need for value-based payments in urologic practices. 
    • Evaluate and determine the benefits of value-based care in the American healthcare system.  
Course summary
Available credit: 
  • 7.00 AMA PRA Category 1 Credit™
  • 7.00 Non-Physician Participation
Course opens: 
01/01/2018
Course expires: 
03/06/2021
Event starts: 
03/04/2019 - 6:00am
Event ends: 
03/06/2019 - 11:59pm
Rating: 
0
Hyatt Regency Capitol Hill
400 New Jersey Avenue, NW
Washington, DC 20001
United States

The AUA Summit will take place from March 4-6, 2019 at the Hyatt Regency Capitol Hill, Washington, D.C. To reserve your hotel for the 2019 AUA Summit, please follow this link and manually select the dates of your stay.

Accreditation: The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation: The American Urological Association designates this live activity for a maximum of 7.00 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Other Learners: The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.

Evidence Based Content: It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.

AUA Disclosure Policy: All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUA must determine if the individual’s relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.

Resolution of Identified Conflict of Interest: All disclosures will be reviewed by the program/course directors or editors for identification of conflicts of interest. Peer reviewers, working with the program directors and/or editors, will document the mechanism(s) for management and resolution of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to resolve conflict of interest:

  • Peer review for valid, evidence-based content of all materials associated with an educational activity by the course/program director, editor, and/or Education Conflict of Interest Review Work Group or its subgroup.
  • Limit content to evidence with no recommendations
  • Introduction of a debate format with an unbiased moderator (point-counterpoint)
  • Inclusion of moderated panel discussion
  • Publication of a parallel or rebuttal article for an article that is felt to be biased
  • Limit equipment representatives to providing logistics and operation support only in procedural demonstrations
  • Divestiture of the relationship by faculty

Off-label or Unapproved Use of Drugs or Devices: The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.

AUA PARTICIPANT INFORMATION & POLICIES

Disclaimer: The opinions and recommendations expressed by faculty, authors and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the AUA.

Consent to Use of Photographic Images: Attendance at or participation in AUA meetings and other activities constitutes an agreement by the registrant to AUA's use and distribution (both now and in the future) of the attendee's image or voice in photographs and electronic reproductions of such meetings and activities.

Audio, Video and Photographic Equipment: The use of audio, video and other photographic recording equipment by attendees is prohibited inside AUA meeting rooms.

Reproduction Permission: Reproduction of written materials developed for this AUA course is prohibited without the written permission from individual authors and the American Urological Association.

Special Assistance/Dietary Needs: The AUA complies with the Americans with Disabilities Act §12112(a). If any participant is in need of special assistance or has any dietary restrictions, please see the registration desk.

Available Credit

  • 7.00 AMA PRA Category 1 Credit™
  • 7.00 Non-Physician Participation

Accreditation Period

Course opens: 
01/01/2018
Course expires: 
03/06/2021
Please login or register to take this course.